---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-25-000046"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2025-10-10T23:59:59+00:00"
generated_at: "2026-05-17T04:04:44.905189+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inspire V clinical data shows superior efficacy, adherence, and reduced surgical times; AHI cut from 34.4 to 8.3

## Summary
- Singapore study (44 patients): Inspire V IPOP 87.1% vs Inspire IV 79.4%, exceeding non-inferiority margin of 4.6%.
- Median AHI reduced from 34.4 to 8.3 events/hour at 6 months for 37 Singapore patients.
- US limited market release (101 patients): no serious adverse events; 100% therapy usage at 60 days; average adherence 6.8 hrs/night.
- AHI for first 34 US patients dropped from 30 to 4.5 events/hour; average stimulation amplitude 1.7V.
- 20% reduction in surgical times; average implant time 34.5 minutes at one site; new internal respiratory sensing eliminates pressure lead.

## SEC filing metadata
- accession: 0001609550-25-000046
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2025-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000046/0001609550-25-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955025000046/insp-20251010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-25-000046
- JSON: https://secwatch.observer/filing/0001609550-25-000046.json
- Plain text: https://secwatch.observer/filing/0001609550-25-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.